Industry experts say the COVID-19 outbreak is unlikely to limit U.S. drug supplies in the short or middle term. However, they tell AIS Health that increased demand for longer-duration stocks of medication from self-isolating patients could strain supplies going forward.
- Datapoint, Drug Benefits
- Abstract, Health Plans
- People on the Move
- Health Plans
- Datapoint, Medicare and Medicaid